On Tuesday (August 28) WeedMD (TSXV:WMD) issued its second quarter results for 2018, the first since a split in its business plan, reporting C$2.1 million in revenue for the quarter ending on June 30.

Keith Merker, CEO of the company, stated the producer has secured supply agreements with the provincial agencies tasked to gather cannabis product for the start of adult-use sales from Nova Scotia, Alberta and B.C.


The licensed producer (LP) also won a supply agreement with retailer Shoppers Drug Mart in June. The deal is set to come into effect if Health Canada approves the Shoppers’ licensed producer application.

WeedMD will supply the pharmacy with medical cannabis to be sold online based on current Canadian restrictions on the sale of medical cannabis in pharmacies.

“Our strains directed at seniors’ and women’s health will add a range of depth to Shoppers Drug Mart’s anticipated medical cannabis product offerings,” Michael Kraft, chairman of WeedMD said at the time.

According to company documents, the producer incurred in a loss of C$1.7 million for the quarter and a diluted loss per share of less than a dollar. The company also reported a cost of C$716,838 for production of its products.

The producer indicated its current C$43 million cash balance will allow it to fund its expansion and business development.

WeedMD also joined one of the latest trends to develop in the cannabis space by announcing a partnership to develop infused beverages with Phivida Holdings (CSE:VIDA). The partnership will see the creation of Cannabis Beverages, a new company which will receive exclusive product from WeedMD.

“WeedMD provides CanBev with solid infrastructure, strong management, world-class genetics and proven success in the Canadian healthcare market,” Jim Bailey, president and CEO of Phivida, said.

In July Canopy Growth (TSX:WEED,NYSE:CGC) swooped in with a surprising acquisition offer for Hiku Brands (CSE:HIKU), a company that was in the process of merging with WeedMD.

The two smaller cannabis companies were set to create a more complete company with expertise on the medical side from WeedMD and knowledge in brands and a potential retail play thanks to Hiku.

WeedMD ended up with a C$10 million termination fee, which Merker told shareholders strengthen the company’s cash position moving forward.

Investor takeaway

With the stage set for recreational sales beginning October 17 in Canada, WeedMD has secured key supply agreements to enter the space directly. Merker expects the company to count with 500,000 square feet of “fully-funded production space online by the end of this year.”

Following the drop from Hiku, Greg McLeish, an analyst with Mackie Research Capital, retained his “Buy” rating in WeedMD and his one-year price target of C$4 for shares of the company.

At the end of the trading session on Tuesday, WeedMD shares were valued at C$1.82, representing a marginal rise of 0.55 percent from its previous closing price.

Don’t forget to follow us @INN_Cannabis for real-time news updates!

Securities Disclosure: I, Bryan Mc Govern, hold no direct investment interest in any company mentioned in this article.

Agreement propels development of safe and effective proprietary products and formulations for the emerging psychedelic industry

Optimi Health Corp. (CSE: OPTI) (“Optimi” or the “Company”), developers of a vertically integrated functional mushroom brand focused on the health and wellness sector, is pleased to announce that effective January 4, 2021, it entered into a lab services agreement with Numinus Wellness Inc. (“Numinus“). Recognized as an early leader in developing and supporting the safe, evidence-based, accessible use of psychedelic-assisted psychotherapies (PAP), Numinus is aiding Optimi’s mission to further the research and development of Canadian-grown psilocybin-producing mushrooms and related product formulations.

Keep reading... Show less

Nextleaf Solutions Ltd. (CSE: OILS) (OTCQB: OILFF) (“Nextleaf”, “OILS”, or the “Company”), the world’s most innovative cannabis processor, is pleased to provide shareholders with the following corporate update:

Nextleaf Comments on Financial Results from Q1 Financials

Keep reading... Show less

Hill Street Beverage Company Inc. (TSXV: BEER) (“Hill Street” or the “Company”) reported its second quarter results for the period ended December 31, 2020. A complete set of financial statements and Management’s Discussion & Analysis has been filed at www.sedar.com. All dollar figures are quoted in Canadian dollars.

The second quarter of FY21, saw continued momentum for the Company despite ongoing pandemic related challenges. Net revenue grew 8% to $745,748 from $689,276 versus the same quarter year ago. The Company also saw significant improvement on its bottom line, reducing its net loss by 50% from ($.956) million to ($.481) million, year over year for the quarter, as a result of improved gross margin and cost management efforts. On December 9, 2020, the company announced the closing of the acquisition of substantially all of the assets of Lexaria Canpharm (“Canpharm“), the cannabis products division of Lexaria Biosciences, resulting in the addition of a new B2B Line of Business.

Keep reading... Show less

Royalty Model Provides Access to Early Stage Licenced U.S. Cannabis Companies and Leverage to High-Margin Revenues

FinCanna Capital Corp. (“FinCanna” or the “Company”) (CSE:CALI), a royalty company for the licensed U.S. cannabis industry, is pleased to provide a corporate update further to its recently announced upsized financing of $2 million

Keep reading... Show less

Significant progress made as Numinus-sponsored PRIME study on psilocybin-assisted psychotherapy for opioid, stimulant and/or alcohol use disorders enters pre-implementation stage

Numinus Wellness Inc. (“Numinus” or the “Company”) (TSXV: NUMI), a company creating an ecosystem of health solutions centered around developing and supporting the safe, evidence-based, accessible use of psychedelic-assisted psychotherapies (PAP), and Syreon Corporation (Syreon), a global contract research organization with expertise in conducting clinical trials across a broad range of diseases, are pleased to share that significant progress has been made in the single-arm, open-label compassionate access 1 trial of Psilocybin-Research Intervention with Motivational Enhancement (PRIME) for substance use disorders. Currently in the development stage, the PRIME study will assess the efficacy and safety of psilocybin-assisted motivational enhancement therapy.

Keep reading... Show less